European Journal of Biomedical and Pharmaceutical Sciences

LIQUID BIOPSY ADVANCES: TRANSFORMING CANCER DIAGNOSIS AND MANAGEMENT

Kondumahanti Venkata Naga Lakshmi*, Mohammad Johaparvaz, Devanaboyina Narendra

ABSTRACT

Liquid biopsy has emerged as a transformative innovation in oncology, offering a minimally invasive alternative to traditional tissue biopsy for cancer detection, monitoring, and characterization. By analysingtumour-derived biomarkers such as circulating tumor DNA (ctDNA), circulating tumour cells (CTCs), exosomes, and microRNAs in blood or other body fluids, liquid biopsy provides a dynamic and repeatable window into tumor biology. This approach addresses key limitations of conventional biopsy, including invasiveness, sampling bias, and inability to capture tumour heterogeneity across primary and metastatic sites. Recent advances in ctDNA detection have significantly improved sensitivity, enabling the identification of tumour-specific mutations at very low concentrations. These developments allow for early cancer diagnosis, real-time monitoring of treatment response, and detection of minimal residual disease (MRD) long before radiological evidence of relapse. Parallel progress in exosome profiling has expanded the biomarker repertoire, as exosomes carry nucleic acids and proteins that reflect the molecular state of tumors. Their analysis is increasingly recognized as a reliable tool for predicting prognosis and guiding therapeutic decisions. Another major breakthrough lies in multi-omics integration, where genomics, transcriptomics, proteomics, and metabolomics are combined to generate comprehensive tumor signatures. Artificial intelligence (AI) and machine learning algorithms are now being applied to interpret these complex datasets, enhancing diagnostic accuracy and predictive power. Such integration is paving the way for personalized oncology, where treatment strategies can be adapted dynamically to evolving tumor biology. Clinically, liquid biopsy is being validated across multiple applications. Multi-cancer early detection (MCED) tests are showing promise for population-level screening, while ctDNA assays are increasingly used to monitor immunotherapy and chemotherapy response.

Keywords: Liquid biopsy, oncology innovation, ctDNA, CTCs, exosomes, microRNAs, tumor heterogeneity, early diagnosis, MRD detection.